Sapience Reports Positive Glioblastoma Trial Data
TARRYTOWN, N.Y., May 21, 2026 Sapience Therapeutics has announced encouraging updated clinical data from its ongoing Phase 2 trial...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TARRYTOWN, N.Y., May 21, 2026 Sapience Therapeutics has announced encouraging updated clinical data from its ongoing Phase 2 trial...
SEOUL, South Korea, May 18, 2026 LOTTE Biologics announced an expanded antibody manufacturing collaboration with Ottimo Pharma to support...
ZURICH, Switzerland – February 27, 2026 Veraxa Biotech AG announced that its shareholders have approved the previously disclosed business...
NEW YORK, NY — December 5, 2025 — OS Therapies Inc. announced two major regulatory milestones advancing its lead...
